Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Clinical trials

A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes

Nature Reviews Nephrology volume 20, page 493 (2024)Cite this article

Subjects

Recent data from a pre-specified analysis of the SELECT trial show a beneficial effect of the glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide on kidney outcomes in patients with cardiovascular disease and overweight or obesity without diabetes. These findings were presented at the 61st European Renal Association Congress in Stockholm.

The SELECT trial, which included 17,604 participants with cardiovascular disease and BMI ≥27 kg/m2 without diabetes, showed that once-weekly treatment with subcutaneous semaglutide (2.4 mg) was associated with a 20% reduction in major cardiovascular events compared with placebo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Nephrology http://www.nature.com/nrneph

    Ellen F. Carney

Authors
  1. Ellen F. Carney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ellen F. Carney.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carney, E.F. A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes. Nat Rev Nephrol 20, 493 (2024). https://doi.org/10.1038/s41581-024-00865-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-024-00865-7

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing